International Patent Strategies for Biopharmaceutical SMEs in Canada
This publication is available upon request in accessible formats.
Contact:Multimedia Services Section
Communications and Marketing Branch
Industry Canada
Room 441E, East Tower
235 Queen Street
Ottawa ON K1A 0H5
Telephone: 613-995-8552
Fax: 613-954-6436
Email: multimedia.production@ic.gc.ca
Release Note:
Published by Industry Canada, March 2013.
Summary: This report was commissioned by Industry Canada to examine the current state of international patent strategies for biopharmaceutical small and medium-sized enterprises (SMEs). It provides an overview of typical patent strategies of SMEs, and includes some of the “best practice” international patent strategies that Canadian biopharmaceutical SMEs can use to position themselves favourably to attract venture capital investment and pharmaceutical partners. Patent checklists that are typically used by investors and Big Pharma to evaluate the patent programs of SMEs are included. Strategic considerations for developing a biopharmaceutical SME’s patent program and budgets are also addressed.
Permission to reproduce:
Non-commercial Reproduction
Except as otherwise specifically noted, the information in this publication may be reproduced, in part or in whole and by any means, without charge or further permission from Industry Canada, provided that due diligence is exercised in ensuring the accuracy of the information reproduced; that Industry Canada is identified as the source institution; and that the reproduction is not represented as an official version of the information reproduced, nor as having been made in affiliation with, or with the endorsement of, Industry Canada.
Commercial Reproduction
For permission to reproduce the information in this publication for commercial redistribution, please contact:
Industry Canada
Pharmaceutical Sector Directorate
235 Queen Street, Room 727E
Ottawa, Ontario K1A 0H5
Canada
Internet: lifesciences.ic.gc.ca
Disclaimer:
Funding for this report was provided by Industry Canada. The views and opinions expressed in the report are those of the author alone and do not represent, in any way, the views or opinions of the Department of Industry or of the Government of Canada.
Prepared by:
Torys LLP for Industry Canada’s Pharmaceutical Sector Directorate
- Date modified:
